New York Blood Center Enterprises and Human Life CORD sign agreement to expand umbilical-derived mesenchymal stem cell manufacturing in the West
Leveraging NYBCe's CDMO subsidiary, the companies plan on bridging the gap between Asian and American manufacturing standards. This collaboration seeks to tackle industry-wide GMP capacity challenges, making advanced cell therapies more accessible worldwide
New York Blood Center Enterprises (NYBCe) and Human Life CORD Japan Inc. (Human Life CORD) have signed an agreement to expand their mesenchymal stem cell manufacturing capabilities through NYBCe’s call manufacturing business unit: Comprehensive Cell Solutions (CCS).
Human Life CORD wants to harmonize its manufacturing platform between Asia and the West, establishing operations in North America soon. To pull it off, they’ve selected CCS due to its extensive experience in advanced cell manufacturing.
CCS is a CDMO operating in Louisville, Kentucky; Houston, Texas; and New York City. They mention expertise with a pretty broad variety of cell therapies, including: CAR-T cells, hematopoietic stem cells (HSCs), mesenchymal stromal cells (MSCs), natural killer (NK) cells, tumor-infiltrating lymphocytes (TILs), and macrophages.
“We are excited to partner with CCS of NYBCe to expand the manufacturing capabilities of umbilical cord-derived MSCs to a global standard. By combining expertise from Japan and the U.S., we aim to establish a highly reproducible and scalable platform, making advanced cell therapy more accessible worldwide”, said Masamitsu Harata, Representative Director, President and CEO, Human Life CORD.
Due to limited Good Manufacturing Practice (GMP) manufacturing capacity in the cell therapy industry, CCS reports that it provides comprehensive services including cell sourcing, patient apheresis, GMP manufacturing, cryopreservation (freezing cells for long-term storage), and logistics support.
